In glioblastoma, HER2-targeted CAR-NK cells paired with anti-PD-1 therapy not only induced tumor regression and prolonged survival but also remodeled the tumor microenvironment by increasing infiltration of CD4+ T cells and a unique natural killer T (NKT) cell subset, highlighting immune reprogramming [90]. Here, PDCD1 is linked to neoplasm.